Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) hasn’t exactly had a bad year — CYCC stock was up 15.5% for the year through Friday. That’s plenty enough to celebrate considering the iShares Nasdaq Biotechnology …
Cyclacel
ETFs by nature are passive index-followers, so as long as the stock remains in the index, it doesn't much matter whether analysts find the stock overvalued or undervalued. Below are some of the ETFs that hold CYCC at last …
Target
Trading of the Company’s common stock on The NASDAQ Capital Market will continue, on a split-adjusted basis, with the opening of the markets on Tuesday, May 31, 2016, under the existing trading symbol “CYCC” and …
Cyclacel Pharmaceuticals updated its Phase 1 data from the DNA damage response program, and presented …
On Monday, shares of Cyclacel Pharmaceuticals (CYCC - Free Report) are skyrocketing, up over 50% after the company reported positive Phase 1 data for one of its lead drug candidates. The trial revolves around Seliciclib, …
ZACKS8mon
Cyclacel
Cyclacel Pharmaceuticals is having an incredible day in the market today, and for good reason. Early this morning, the company reported Phase 1 data surrounding one of its lead candidates, and that data was …
At close on Tuesday, the biopharmaceutical company had a market capitalization of $82.65M and ANTH stock
Cyclacel
Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) (Nasdaq: CYCCP) (Cyclacel or the Company), today announced the pricing of the underwritten offering of 6,666,667 shares of its common stock at a price to the public of …